Amphastar Pharmaceuticals (AMPH) Non-Current Debt (2013 - 2026)

Amphastar Pharmaceuticals' Non-Current Debt history runs 14 years deep, the most recent figure standing at $609.8 million for Q1 2026.

• In Q1 2026, Non-Current Debt rose 0.98% year-over-year to $609.8 million; the TTM figure through Mar 2026 stood at $609.8 million (up 0.98% YoY), while the FY2025 annual figure was $608.7 million, up 1.18% from the prior year.
• Non-Current Debt was $609.8 million for Q1 2026 at Amphastar Pharmaceuticals, roughly flat from $608.7 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $638.2 million in Q3 2023 to a low of $72.8 million in Q4 2022.
• Historically, Non-Current Debt has averaged $441.3 million across 5 years, with a median of $594.0 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Non-Current Debt surged 762.31% in 2023, then declined 6.54% in 2024.
• A 5-year view of Non-Current Debt shows it stood at $72.8 million in 2022, then surged by 709.43% to $589.6 million in 2023, then advanced by 2.04% to $601.6 million in 2024, then advanced by 1.18% to $608.7 million in 2025, then gained by 0.17% to $609.8 million in 2026.
• The last three Non-Current Debt figures came in at $609.8 million (Q1 2026), $608.7 million (Q4 2025), and $608.6 million (Q3 2025), per Business Quant data.